Prothena

Roche app measures Parkinson’s disease fluctuations

Monday, August 17, 2015

Roche Pharma Research & Early Development (pRED) has developed a smartphone-based monitoring system for those with Parkinson’s disease (PD) that complements the traditional physician-led assessments with automated tests that continuously measure their symptom fluctuations. It could be the first time that such an app has been used to measure disease and symptom severity in a medicine development program in PD.

[Read More]

Roche, Prothena collaborate for Parkinson’s disease

Friday, December 13, 2013

Roche and Prothena have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein including PRX002, Prothena’s monoclonal antibody for the treatment of Parkinson’s disease, which currently is in preclinical development and is expected to enter phase I clinical trials in patients with Parkinson’s in 2014.

[Read More]

Elan completes demerger of Prothena

Friday, December 21, 2012

Dublin-based Elan has completed the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena. Incorporated in Ireland, Prothena commenced trading on the NASDAQ Global Market as of Dec. 21.

[Read More]